Posted by Michael Wonder on 04 Mar 2019
Intellipharmaceutics announces resubmission of new drug application to the U.S. FDA for its oxycodone ER
4 March 2019 - Intellipharmaceutics today announced that it has resubmitted its new drug application to the U.S. FDA for its oxycodone ER product candidate.
The Company's application for an abuse-deterrent version of oxycodone ER was initially accepted for filing by the FDA in February 2017.
